Does Cefazolin Cover Gram-Positive Bacilli?
Cefazolin does NOT provide reliable coverage against gram-positive bacilli, as it is specifically designed for gram-positive cocci (staphylococci and streptococci) and has limited activity against bacillary organisms. 1, 2
Cefazolin's Antimicrobial Spectrum
Gram-Positive Coverage Profile
- Cefazolin has excellent activity against methicillin-sensitive Staphylococcus aureus (MSSA) and beta-lactam susceptible streptococci, which are gram-positive cocci, not bacilli 1, 2
- The FDA label specifically identifies cefazolin's gram-positive activity as limited to: Staphylococcus aureus (including beta-lactamase-producing strains), Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus agalactiae, other streptococci, and Streptococcus pneumoniae - all of which are cocci 2
- First-generation cephalosporins like cefazolin are "most active against sensitive staphylococci and streptococci" but lack meaningful activity against gram-positive bacilli 3
Critical Coverage Gaps
- Cefazolin has no enterococcal coverage, which is clinically significant since enterococci are gram-positive bacilli that commonly cause infections 1
- Cefazolin has no anaerobic coverage, requiring combination with metronidazole for infections involving Bacteroides fragilis and other obligate anaerobes, many of which are gram-positive bacilli 1
- The drug demonstrates activity primarily against gram-positive cocci and select gram-negative organisms (E. coli, Proteus mirabilis, Klebsiella), but gram-positive bacilli are notably absent from its spectrum 2, 4
Clinical Implications
When Cefazolin Is Appropriate
- The Infectious Diseases Society of America recommends cefazolin for MSSA skin and soft tissue infections where narrower spectrum targeting gram-positive cocci is adequate 1
- Cefazolin is recommended for surgical prophylaxis in clean or clean-contaminated procedures, again targeting cocci rather than bacilli 1
- Fortified cefazolin/tobramycin combination therapy has been used for bacterial keratitis, with the tobramycin component providing gram-negative coverage while cefazolin targets gram-positive cocci 5, 6
Common Pitfalls to Avoid
- Do not assume cefazolin covers all gram-positive organisms simply because it excels against MSSA and streptococci - the distinction between cocci and bacilli is critical 1, 2
- For polymicrobial infections involving gram-positive bacilli (such as enterococci) or anaerobes, cefazolin monotherapy is inadequate and requires combination therapy or alternative agents like amoxicillin-clavulanate 1
- Methicillin-resistant staphylococci are uniformly resistant to cefazolin, requiring vancomycin instead 2
Alternative Agents for Gram-Positive Bacilli
- Amoxicillin-clavulanate (Clavulin) provides limited enterococcal activity against ampicillin-susceptible strains and has excellent anaerobic coverage including gram-positive bacilli 1
- For vancomycin-resistant enterococcus (a gram-positive bacillus), ampicillin at high doses (18-30 g IV daily) or linezolid are appropriate options 7
- Newer agents like ceftaroline (fifth-generation cephalosporin) have activity against vancomycin-resistant Enterococcus faecalis but not E. faecium, though ceftaroline has limited activity against anaerobic gram-positive bacilli like Bacteroides fragilis 8